The probe is directed at all CAR-Ts currently on the US market, including those that target CD19, as well as BCMA, ... As part of post-CAR-T therapy safety and surveillance, ...

CAR T cell therapy is a promising approach to treatment that might have the potential to put lupus into remission for long periods for some patients. However, it is very early in the research process ...

Patients develop T cell lymphomas after CAR-T therapy extremely rarely — less than 0.1% of the time, Rejeski said. Second cancers also rarely cause death in CAR-T patients, Rejeski said.

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with remission rates reaching as high as 90%. This therapy modifies a patient ...

A recent study led by investigators at MSK and published in Nature Medicine, included a comprehensive analysis of non relapse mortality after CAR T cell therapy in patients with lymphoma and multiple ...

While CAR T cell therapy -- a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn -- has revolutionized treatment for many blood cancers ...

Chimeric antigen receptor (CAR) T-cell therapy has been an exciting area of development for autoimmune disease treatment. Previous reports had not mentioned any particular constellation of adverse ...

Citation: Successful CAR-T cell therapy for end-stage multiple myeloma using advanced cellular product performed in Hong Kong (2025, March 27) retrieved 3 July 2025 from https://medicalxpress.com ...

A CAR T cell therapy clinical trial is conducted by a multidisciplinary care team that oversees the preparation, administration, and follow up of the therapy. The clinical trial care team consists of ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. The findings, led by researchers in the Perelman ...